Global ETD Search

1	Effects of Low Dose Aspirin (81 mg) on Proliferating Cell Nuclear Antigen and Amaranthus Caudatus Labeling in Normal-Risk and High-Risk Human Subjects for Colorectal Cancer Krishnan, Koyamangalath, Aoki, Toshihiro, Ruffin, Mack T., Normolle, Daniel P., Boland, C. Richard, Brenner, Dean E. 20 April 2004 (has links) Epidemiological, experimental, and clinical observations provide support for a colorectal cancer chemopreventive role for aspirin. We have evaluated the effects of aspirin on proliferation biomarkers in normal-risk and high-risk human subjects for colorectal cancer. Colorectal biopsies were obtained at baseline and at 24h after 28 daily doses of 81mg of aspirin from 13 high-risk and 15 normal-risk subjects for colorectal cancer. We evaluated aspirin's effects on proliferating cell nuclear antigen (PCNA) immunohistochemistry and epithelial mucin histochemistry using the lectin, Amaranthus caudatus agglutinin (ACA) in crypt sections from rectal biopsies. The baseline whole crypt PCNA LIs differed significantly between normal-risk and high-risk subjects. PCNA LIs are not affected by 28 days of aspirin at 81mg daily. ACA LIs are decreased by 28 days of aspirin at 81mg daily in both normal-risk and high-risk subjects. Aspirin's effects on ACA LIs may have mechanistic and biological implications that deserve further attention. PCNA and ACA LIs are not useful as proliferation biomarkers for aspirin's chemopreventive activity in morphologically normal human colorectal mucosa. ACA amaranthus caudatus agglutinin aspirin colon cancer chemoprevention EIA enzyme immunosorbent assay familial adenomatous polyposis FAP HNPCC labeling index LI MAb monoclonal antibody PCNA proliferating cell nuclear antigen proliferation markers Internal Medicine

Search results

Effects of Low Dose Aspirin (81 mg) on Proliferating Cell Nuclear Antigen and Amaranthus Caudatus Labeling in Normal-Risk and High-Risk Human Subjects for Colorectal Cancer